Опубликована: Март 5, 2024
Frontiers in Pharmacology, Год журнала: 2024, Номер 15
Опубликована: Апрель 22, 2024
Introduction: Although post-COVID-19 syndrome (PCS) with cognitive impairment is increasingly encountered in primary care, evidence-based recommendations for its appropriate management are lacking. Methods: A systematic literature search evaluating the diagnosis and treatment of associated PCS was conducted. Practical PCS-associated care summarized, based on an evaluation pharmacological plausibility clinical applications. Results: Currently, pathology remains unclear no high-quality data to support targeted interventions. Existing approaches directed towards symptom relief where counseling chronicity disease regular reassessments at 4- 8-week intervals considered reasonable. Patients should be informed encouraged adopt a healthy lifestyle that centers around balanced nutrition physical activities. They may also benefit from intake vitamins, micronutrients, probiotics. The administration Ginkgo biloba extract could offer safe potentially beneficial option. Other non-pharmacological measures include physiotherapy, digitally supported training, and, if indicated, ergotherapy or speech therapy. In most patients, symptoms improve within 8 weeks. If serious, ambiguous, when new occur, specialized diagnostic such as comprehensive neurocognitive testing neuroimaging initiated. Very few patients would require inpatient rehabilitation. Conclusion: debilitating condition affect daily functioning reduce work productivity. Management multidisciplinary approach, centering physical, cognitive, therapies.
Язык: Английский
Процитировано
5
Annals of Clinical and Translational Neurology, Год журнала: 2024, Номер 11(9), С. 2457 - 2472
Опубликована: Июль 30, 2024
Abstract Objective The aim of this study was to assess COVID‐19‐related gray matter (GM) structural alterations in two distinct groups patients presenting with the prevailing and distinctive neurological symptoms – isolated olfactory disorders as sole manifestation (COVID‐OD) cognitive (COVID‐CD) compared a control group unaffected individuals. Methods included 61 COVID‐CD (57 [60–63] years, 62% females), 84 COVID‐OD (49 [35–57] 60% 17 controls (51 [41–52] 41% females). Region‐based morphometry (RBM) voxel‐based (VBM) were performed on T1‐weighted MRI scans GM regional volume voxel‐wise density differences between COVID‐19 controls. Surface‐based (SBM) applied investigate cortical thickness alterations. statistical models built among total intracranial age nuisance variables. Results multi‐morphometric analysis revealed statistically significant ( p < 0.05 corrected for multiple comparisons) reduction volumes, both patient Across all three analyses, showed more distributed severe loss than patients. most prominently affected regions hippocampus, putamen, cingulate gyrus, precuneus, precentral postcentral gyri, amygdala, lingual caudate nucleus. Interpretation Our findings show that induce atrophy, although at different degrees severity, likely indicative neurodegeneration neuroinflammation.
Язык: Английский
Процитировано
3
Brain and Behavior, Год журнала: 2024, Номер 14(10)
Опубликована: Окт. 1, 2024
Many patients report neuropsychiatric symptoms after SARS-CoV-2 infection. Data on prevalence of post-COVID-19 condition (PCC) vary due to the lack specific diagnostic criteria, unspecific symptoms, and reliable biomarkers.
Язык: Английский
Процитировано
2
Frontiers in Neurology, Год журнала: 2024, Номер 15
Опубликована: Сен. 3, 2024
Purpose The COVID-19 pandemic has led to millions of confirmed cases worldwide, resulting in numerous deaths and hospitalizations. Long-term symptoms after infection or vaccination, known as Post-acute Syndrome (PACS) Vaccination (PACVS), present a challenge for the healthcare system. Among various neurological symptoms, cognitive impairments are frequently observed PACS/PACVS patients. This study aimed understand deficits patients evaluated potential treatment options, including phosphatidylcholine computer-assisted training (CCT). Methods Neuro-COVID Outpatient Clinic at Evangelic Hospital Vienna n = 29 from May 2023 October 2023. Enrolled were divided into three therapy schemes: Group A received phosphatidylcholine, B plus access program, C (divided two subgroups) served control group. Cognitive multiple assessments (initial during therapy) using COGBAT test. Simultaneously, an assessment quality life was conducted WHOQOL-BREF. Results Primary impairments, especially attentional notably evident compared general population. While all groups showed improvement (significant with positive trend, but without reaching level statistical significance) therapy, no significant interaction found between time points schemes overall performance, attention, memory, executive functions, suggesting consistency across groups. WHOQOL-BREF primarily demonstrated domains physical health psychological well-being. Conclusion examined impact on performance CCT options. Patients notable deficits, domain attention. effectiveness treating inconclusive, indicated possibility spontaneous remission PACS/PACVS.
Язык: Английский
Процитировано
1
Опубликована: Март 5, 2024
Процитировано
0
Therapeutic Advances in Neurological Disorders, Год журнала: 2024, Номер 17
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0
Springer eBooks, Год журнала: 2024, Номер unknown, С. 177 - 186
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0
Опубликована: Март 5, 2024
Процитировано
0
Опубликована: Март 5, 2024
Процитировано
0
Опубликована: Март 5, 2024
Процитировано
0